1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors.
Saved in:
| Title: | 1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors. |
|---|---|
| Authors: | Chauhan, A.1 (AUTHOR), Reis, I.2 (AUTHOR), Jani, C.T.3 (AUTHOR), Modak, R.1 (AUTHOR), Bilbao, D.4 (AUTHOR), Merchan, J.R.5 (AUTHOR), Lopes, G.6 (AUTHOR), Hosein, P.7 (AUTHOR), Hallenbeck, P.8 (AUTHOR), Trinh, H.9 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1019-S1019. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 189420147 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Chauhan%2C+A%2E%22">Chauhan, A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Reis%2C+I%2E%22">Reis, I.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jani%2C+C%2ET%2E%22">Jani, C.T.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Modak%2C+R%2E%22">Modak, R.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bilbao%2C+D%2E%22">Bilbao, D.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Merchan%2C+J%2ER%2E%22">Merchan, J.R.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lopes%2C+G%2E%22">Lopes, G.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hosein%2C+P%2E%22">Hosein, P.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hallenbeck%2C+P%2E%22">Hallenbeck, P.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Trinh%2C+H%2E%22">Trinh, H.</searchLink><relatesTo>9</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS1019-S1019. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189420147 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.08.2361 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S1019 Titles: – TitleFull: 1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Chauhan, A. – PersonEntity: Name: NameFull: Reis, I. – PersonEntity: Name: NameFull: Jani, C.T. – PersonEntity: Name: NameFull: Modak, R. – PersonEntity: Name: NameFull: Bilbao, D. – PersonEntity: Name: NameFull: Merchan, J.R. – PersonEntity: Name: NameFull: Lopes, G. – PersonEntity: Name: NameFull: Hosein, P. – PersonEntity: Name: NameFull: Hallenbeck, P. – PersonEntity: Name: NameFull: Trinh, H. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2025 Supplement 2 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 36 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
